| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.19 | 6e-05 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0006 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.17 | 0.001 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.18 | 0.001 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.16 | 0.002 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.13 | 0.005 |